CLP36 promotes p53 deficient sarcoma progression through suppression of atrophin-1 interacting protein-4 (AIP-4)-dependent degradation of YAP1.

Theranostics · 2022 · PMC9274740 · PMID 35836803

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, KO of CLP36 only marginally increased the ratio of Ser127 phosphorylated YAP1/total YAP1, which did not reach statistical significance ( Figure S6 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.